Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014
Dateline City:
WHITEHOUSE STATION, N.J.
Company to Initiate Phase 3 Clinical Development Program in Q2 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new Phase 2 data for its two investigational
hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV
NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A
replication complex inhibitor – are scheduled to be presented at the 49th
Annual Meeting of the European Association for the Study of the Liver
(EASL), also known as The International Liver Congress™ 2014.
Language:
English
Contact:
MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Study | Urology & Nephrology